Theory Paper IIIDrNB Cardiology – Theory Notes
ADVANCES IN MANAGEMENT OF CTEPH
IINTRODUCTION AND DIAGNOSTIC ADVANCES
- Definition: Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a progressive Group 4 Pulmonary Hypertension characterized by organized fibrotic thromboemboli in the pulmonary arteries and a secondary microvascular arteriopathy.
- Hemodynamic Criteria: Mean pulmonary artery pressure (mPAP) greater than 20 mmHg, pulmonary arterial wedge pressure (PAWP) 15 mmHg or less, and pulmonary vascular resistance (PVR) greater than 2 Wood Units after 3 or more months of effective anticoagulation.
- Imaging Advances: While planar V/Q scan remains the Class I screening tool, Dual-Energy CT (DECT) and 3D V/Q SPECT have emerged as advanced modalities to map the pulmonary tree and assess segmental operability without invasive angiography.
IISURGICAL ADVANCES: REFINING THE GOLD STANDARD
- Surgical Technique: Pulmonary Endarterectomy (PEA) performed under Deep Hypothermic Circulatory Arrest (DHCA) enables surgeons to dissect the fibrotic intimal layer down to the sub-segmental level, expanding the boundaries of operability.
- Clinical Evidence: Data from the International CTEPH Registry show that in high-volume expert centers, operative mortality has fallen to less than 5 percent, with sustained reductions in PVR.
- Guideline Recommendation: Class I, LOE B for all patients with anatomically accessible (operable) CTEPH.
IIIINTERVENTIONAL ADVANCES: THE CATH-LAB REVOLUTION
- Balloon Pulmonary Angioplasty (BPA): Uses coronary or peripheral balloons to crack and dilate organized fibrotic webs in distal, surgically inaccessible branches over 4 to 6 staged sessions.
- The Landmark Evidence (RACE Trial): Compared BPA versus Riociguat in inoperable CTEPH and demonstrated that BPA provides superior hemodynamic improvements (reduction in PVR) compared to medical therapy, though it carries a higher upfront risk of Reperfusion Pulmonary Edema (RPE).
- Guideline Recommendation: Class I, LOE B for technically inoperable CTEPH or persistent/recurrent PH after PEA.
IVPHARMACOLOGICAL ADVANCES: TARGETING THE MICROVASCULATURE
ASoluble Guanylate Cyclase (sGC) Stimulators
- Mechanism (Riociguat): Directly sensitizes sGC to endogenous nitric oxide and stimulates the receptor independently of NO, causing pulmonary vasodilation.
- Landmark Trials (CHEST-1 and CHEST-2): Demonstrated significant improvements in 6-minute walk distance (6MWD) and PVR.
- Guideline Recommendation: Class I, LOE B as the approved drug for inoperable CTEPH or persistent/recurrent PH post-PEA.
BEndothelin Receptor Antagonists (ERAs)
- Landmark Evidence (MERIT-1 Trial): Showed that adding Macitentan significantly improves PVR in inoperable CTEPH patients, supporting combination medical therapy.
- Guideline Recommendation: Class IIb, LOE B for symptomatic inoperable patients.
CSubcutaneous Prostacyclins
- Landmark Evidence (CTREPH Trial): Demonstrated the efficacy of subcutaneous Treprostinil in severe inoperable CTEPH, providing a rescue option for WHO Functional Class III/IV patients.
| Modality / Agent | Target Pathology | Landmark Trial / Registry | Guideline Status |
|---|---|---|---|
| Pulmonary Endarterectomy (PEA) | Proximal / segmental fibrotic thromboemboli | International CTEPH Registry | Class I, LOE B for operable CTEPH |
| Balloon Pulmonary Angioplasty (BPA) | Distal, surgically inaccessible webs | RACE Trial | Class I, LOE B for inoperable or persistent post-PEA PH |
| Riociguat (sGC Stimulator) | Secondary distal microvascular arteriopathy | CHEST-1 & CHEST-2 Trials | Class I, LOE B for inoperable or persistent post-PEA PH |
| Macitentan (ERA) | Microvascular remodeling | MERIT-1 Trial | Class IIb, LOE B in symptomatic inoperable CTEPH |
| Subcutaneous Treprostinil | Severe microvascular disease (WHO FC III/IV) | CTREPH Trial | Rescue therapy in severe inoperable CTEPH |
VTHE PARADIGM SHIFT AND THE INDIAN CLINICAL CONTEXT
- The Multimodal CTEPH Heart Team (Class I, LOE C): CTEPH management has shifted from a binary operable-versus-inoperable approach to a hybrid multimodal paradigm where a single patient may undergo PEA for proximal clots, followed by BPA for residual distal webs, and lifelong Riociguat for microvascular disease.
- Diagnostic Mimics in the Indian Context: In the Indian subcontinent, Fibrosing Mediastinitis (post-Tuberculosis) and Takayasu Arteritis frequently mimic CTEPH on imaging; detailed clinical history and DECT are essential to rule these out before attempting PEA or BPA.
- BPA Accessibility: Because expert PEA surgical centers are concentrated in a few major metropolitan cities, BPA serves as an important frontline intervention in Tier-1 catheterization laboratories across India for patients who cannot access open-heart surgery.
Key references
- Libby P, Bonow RO, Mann DL, Tomaselli GF, Bhatt DL, Solomon SD: Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 12th Ed., Elsevier, 2022.
- Ghofrani HA, D’Armini AM, Grimminger F, et al. (CHEST-1 Investigators): Riociguat for the treatment of chronic thromboembolic pulmonary hypertension, New England Journal of Medicine.
- Jaïs X, Brenot P, Bouvaist H, et al. (RACE Investigators): Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE), The Lancet Respiratory Medicine.
meritmedscript.comDr. Sidhartha Mullapudi
